Cyanosis primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(8 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
Effective measurement for primary prevention include prenatal [[echocardiography]] and [[genetic]] testing for detecting [[cyanotic congenital heart disease]] and prenatal [[corticosteroid]] therapy for prevention of neonatal [[respiratory distress syndrome]] and development of lung maturation.


== Prenatal diagnosis ==
== Primary prevention ==
Clinicians skilled at fetal echocardiography are able to identify most congenital heart defects. However, clinical suspicion or a risk factor for CHD must be identified to prompt referral for fetal echocardiography. Routine antenatal ultrasound traditionally included assessment of the fetal heart using the four chamber view; however, the practice guidelines of the International Society for Ultrasound in Obstetrics and Gynecology (ISUOG) published in 2013 now recommend expanded views for screening, including assessment of the outflow tracts [41]. Studies performed in the era prior to publication of these guidelines indicate that less than half of patients with critical congenital heart defects were routinely identified [10,42-44]. CHD lesions involving abnormal outflow tracts (including tetralogy of Fallot (figure 2), double outlet right ventricle [DORV], and transposition of the great arteries [TGA] (figure 3)) are particularly at risk for not being identified. In addition, coarctation of the aorta (COA) (figure 4) is difficult to definitively diagnose prenatally.


The expanded prenatal screening recommendations of the ISUOG may lead to improved detection rates in the future. One study found that the rate of prenatal detection of critical CHD increased from 44 percent in 2007 to 69 percent in 2013 [43].
*Effective measurement for primary prevention include prenatal [[echocardiography]] and [[genetic]] testing for detecting [[cyanotic congenital heart disease]] and prenatal [[corticosteroid]] therapy for prevention of neonatal [[respiratory distress syndrome]] and development of lung maturation.<ref name="LiuXu2019">{{cite journal|last1=Liu|first1=Xiwang|last2=Xu|first2=Weize|last3=Yu|first3=Jiangen|last4=Shu|first4=Qiang|title=Screening for congenital heart defects: diversified strategies in current China|journal=World Journal of Pediatric Surgery|volume=2|issue=1|year=2019|pages=e000051|issn=2516-5410|doi=10.1136/wjps-2019-000051}}</ref>
 
Prenatal sonographic screening for CHD is discussed in detail separately.


==References==
==References==

Latest revision as of 17:55, 6 November 2020

Cyanosis Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cyanosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cyanosis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cyanosis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cyanosis primary prevention

CDC on Cyanosis primary prevention

Cyanosis primary prevention in the news

Blogs on Cyanosis primary prevention

Directions to Hospitals Treating Cyanosis

Risk calculators and risk factors for Cyanosis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Effective measurement for primary prevention include prenatal echocardiography and genetic testing for detecting cyanotic congenital heart disease and prenatal corticosteroid therapy for prevention of neonatal respiratory distress syndrome and development of lung maturation.

Primary prevention

References

  1. Liu, Xiwang; Xu, Weize; Yu, Jiangen; Shu, Qiang (2019). "Screening for congenital heart defects: diversified strategies in current China". World Journal of Pediatric Surgery. 2 (1): e000051. doi:10.1136/wjps-2019-000051. ISSN 2516-5410.

Template:WH Template:WS